Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 6/20 | 0.72 |
| ▸ | GRM4 | Q14833 | 7/20 | 0.70 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.70 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.68 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | CES1 | P23141 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30643208 | 1.00 | KDR (0.72) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL259238 | 1.00 | KDR (0.72) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL7990375 | 0.89 | KDR (0.84) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL28036432 | 0.87 | GAA (0.66) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL28871825 | 0.87 | GAA (0.58) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL259290 | 0.84 | RAB9A (0.69) | SMN1; SMN2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL12197847 | 0.84 | GRM4 (0.76) | KDRGRM4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29496401 | 0.83 | GRM4 (1.00) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL2528081 | 0.83 | GRM4 (0.72) | KDRGRM4HDAC6KCNK3KCNK9 | |
| SCHEMBL2530324 | 0.83 | GRM4 (1.00) | KDRGRM4HDAC6KCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119803926-A | Rolling bearing fault diagnosis method, device, equipment, medium and product | 武汉优泰电子技术有限公司 | 2025-04-11 | — | — | CN | claimed |
| EP-4406957-B1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LTD (IE) | 2026-04-08 | — | — | EP | disclosed |
| US-12577256-B2 | Aryl receptor modulators and methods of making and using the same | NOGRA PHARMA LIMITED (IE) | 2026-03-17 | — | — | US | disclosed |
| WO-2025215004-A1 | MANUAL PUMP | ALPLA WERKE ALWIN LEHNER GMBH & CO KG (AT) | 2025-10-16 | — | — | WO | disclosed |
| EP-4630973-A1 | METHOD FOR OBTAINING A DATA GRID CONTAINING DATA REPRESENTATIVE OF A DYNAMICALLY REPRESENTED SCENE, AND CORRESPONDING DEVICE AND PROGRAM | Institut National de Recherche en Informatique et en Automatique (FR) | 2025-10-15 | — | — | EP | disclosed |
| CN-119803926-A | Rolling bearing fault diagnosis method, device, equipment, medium and product | 武汉优泰电子技术有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250066384-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2025-02-27 | — | — | US | disclosed |
| EP-4437485-A2 | TRANSACTION PLATFORMS WHERE SYSTEMS INCLUDE SETS OF OTHER SYSTEMS | Strong Force TX Portfolio 2018, LLC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4406957-A2 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | Nogra Pharma Limited (IE) | 2024-07-31 | — | — | EP | disclosed |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-3160964-B1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| CN-116947880-A | Aryl receptor modulators and methods of making and using the same | 诺格拉制药有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4262831-A1 | METHODS OF CELL THERAPIES | Ossium Health, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-111978319-B | Aryl receptor modulators and methods of making and using the same | 诺格拉制药有限公司 | 2023-08-11 | — | — | CN | disclosed |
| US-20230234963-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | NOGRA PHARMA LIMITED (IE) | 2023-07-27 | — | — | US | disclosed |
| WO-2023097026-A2 | TRANSACTION PLATFORMS WHERE SYSTEMS INCLUDE SETS OF OTHER SYSTEMS | Strong Force TX Portfolio 2018, LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| CN-116009741-A | Clock dial for electronic device | 苹果公司 | 2023-04-25 | — | — | CN | disclosed |
| US-11427600-B2 | Aryl receptor modulators and methods of making and using the same | NOGRA PHARMA LIMITED (IE) | 2022-08-30 | — | — | US | disclosed |
| EP-4031685-A2 | IN VITRO FERTILISATION (IVF) EMBRYO VIABILILITY AND QUALITY ASSAY | University of Tartu (EE) | 2022-07-27 | — | — | EP | disclosed |
| WO-2022133282-A1 | METHODS OF CELL THERAPIES | Ossium Health, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577256-B2 | Aryl receptor modulators and methods of making and using the same | AHR, IL23R, ARNT | KDR 1208/4885GRM4 2239/4885HDAC6 2095/4885 |
| US-20250066384-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | AHR, IFNAR1, IL23R | KDR 1063/4885GRM4 1487/4885HDAC6 1025/4885 |
| US-11427600-B2 | Aryl receptor modulators and methods of making and using the same | AHR, IL23R, IL2RA | KDR 1016/4885GRM4 1206/4885HDAC6 1163/4885 |
| US-12042507-B2 | Compositions and methods of modulating HIF-2A to improve muscle generation and repair | HIF1A, HIF1AN, MYLK2 | KDR 659/4885GRM4 4028/4885HDAC6 1165/4885 |
| US-20230234963-A1 | ARYL RECEPTOR MODULATORS AND METHODS OF MAKING AND USING THE SAME | AHR, IL23R, IL2RA | KDR 1016/4885GRM4 1206/4885HDAC6 1163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.